Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors

Journal Article

It is fairly well accepted that the presence of estrogen receptor (ER) and progesterone receptor (PgR) identifies breast cancer patients with a lower risk of relapse and better overall survival. But patients with discordant receptors, the ER+/PgR- phenotype, are often intermediate in clinical response. We focused upon this group of patients and have identified a truncated ER which is abundant in some ER+/PgR- breast tumors and which inhibits the binding of wild-type ER to its cognate response element. This variant interferes in a dominant negative manner with wild-type ER function and may represent a mechanism for modulation of estrogen responsiveness.

Duke Authors

Cited Authors

  • Fuqua, SAW; Fitzgerald, SD; Allred, DC; Elledge, RM; Nawaz, Z; McDonnell, DP; O'Malley, BW; Greene, GL; McGuire, WL

Published Date

  • 1992

Published In

Volume / Issue

  • 52 / 2

Start / End Page

  • 483 - 486

International Standard Serial Number (ISSN)

  • 0008-5472